Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance

Publication date: Available online 20 May 2018
Source:The Journal of Steroid Biochemistry and Molecular Biology
Author(s): Cristina Amaral, Tiago Vieira Augusto, Elisiário Tavares-da-Silva, Fernanda M.F. Roleira, Georgina Correia-da-Silva, Natércia Teixeira
The leading cause of cancer death in women around the world is breast cancer. The aromatase inhibitors (AIs) are considered a first-line treatment for estrogen receptor-positive (ER⁺) breast tumors, in postmenopausal women. Exemestane (Exe) is a powerful steroidal AI, however, despite its therapeutic success, Exe-acquired resistance may occur leading to tumor relapse. Our group previously demonstrated that autophagy acts as a pro-survival process in Exe-induced cell death of ER⁺ sensitive breast cancer cells. In this work, the role of autophagy and its relationship with the PI3K/AKT/mTOR pathway in Exe-acquired resistance was explored. In that way, the mechanism behind the effects of the combination of Exe with pan-PI3K, or autophagic inhibitors, was studied in a long-term estrogen deprived ER⁺ breast cancer cell line (LTEDaro cells). Our results indicate that Exe induces autophagy as a cytoprotective mechanism linked to acquired resistance. Moreover, it was demonstrated that by inhibiting autophagy and/or PI3K pathway it is possible to revert Exe-resistance through apoptosis promotion, disruption of cell cycle, and inhibition of cell survival pathways. This work provides new insights into the mechanisms involved in Exe-acquired resistance, pointing autophagy as an attractive therapeutic target to surpass it. Thus, it highlights new targets that together with aromatase inhibition may improve ER⁺ breast cancer therapy, overcoming AIs-acquired resistance.



https://ift.tt/2Izz2yr